Clinical trial
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency…
NCT00082628 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00082628 |
|---|---|
| Title | Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients |
| Official title | A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipodystrophy |
| Intervention type | Drug |
| Interventions | Placebo, Serostim® 4 mg, Serostim® 2 mg |
| Enrollment | 326 |
| Start date | May 28, 2004 |
| Primary completion | Sep 28, 2005 |
| Completion | Sep 28, 2005 |
| First posted | May 17, 2004 |
| Last update posted | Jul 20, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: